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Summary
NPM-ALK characterizes anaplastic large cell lymphoma (ALCL), as does the high expression of CD30, a feature shared
with H-RS cells of classic Hodgkin’s lymphoma. In H-RS cells, ligand-independent signaling by overexpressed CD30 drives
constitutive NF-B activation, which is absent in ALCL cells. Here we show that NPM-ALK impedes CD30 signaling and
NF-B activation, dependent on both ALK kinase activity and the N-terminal NPM domain. NPM-ALK transduction into
H-RS cell lines abrogates recruitment and aggregation of TRAF proteins, inducing an ALCL-like morphology and phenotype.
TRAF2 associates with NPM-ALK at a consensus binding motif located in the kinase domain. Thus, NPM-ALK abrogates
CD30-driven NF-B activation and can also induce an ALCL phenotype, distinguishing ALCL cells from H-RS cells of T cell
origin.
Introduction is normally restricted to neural tissues (Iwahara et al., 1997).
When NPM-ALK forms a hexamer at the NPM domain, the
oligomerized ALK domain acts as a constitutively active kinaseAnaplastic large cell lymphoma (ALCL) is a group of large-cell
neoplasms of T lymphocytes characterized by subtotal efface- which is a property of the NPM-ALK oncoprotein (Bai et al.,
1998; Bischof et al., 1997). NPM-ALK is capable of transformingment of the lymph node structure, prominent sinusoidal diffusion
with spread into adjacent paracortical areas, and bizarre/ana- fibroblasts (Wellmann et al., 1997), and inducing a T cell lym-
phoma and plasma cell tumors in mice (Chiarle et al., 2003).plastic morphology (Kadin, 1994). ALCL cells are characterized
by expression of EMA, clusterin, and usual absence of CD15, The presence of NPM-ALK chimeric protein is characteristic
of most systemic/nodal ALCL, and these lymphomas representdiscriminating them from Hodgkin/Reed-Sternberg (H-RS) cells
(Jaffe, 2001). NPM-ALK has been identified in ALCL cells as a clinicopathological entity (Jaffe, 2001).
ALCL cells are characterized by a high level of CD30 expres-a chimeric protein generated by a chromosomal translocation
t(2;5)(p23;q35) that fuses nucleophosmin (NPM) sequences on sion that is a phenotype shared with H-RS cells of classic
Hodgkin’s lymphoma (HL) (Jaffe, 2001; Kadin, 1994; Stein etchromosome 5 to anaplastic lymphoma kinase (ALK) sequences
on chromosome 2 (Morris et al., 1994). al., 2000). CD30 is a member of the TNFR superfamily (Chiarle
et al., 1999; Horie and Watanabe, 1998), and high expressionNPM is a ubiquitously expressed nuclear protein responsible
for protein shuttling between the cytoplasm and nucleus (Borer of CD30 in H-RS cells results in ligand-independent signaling
of CD30 that drives constitutive activation of NF-B (Horie etet al., 1989). NPM has been proposed to function in ribosomal
protein assembly and transport (Olson et al., 1986), and also al., 2002b, 2003). However, NF-B activation is not observed
in ALCL cells in the presence of equivalent levels of CD30 ex-as a molecular chaperone that prevents proteins from aggregat-
ing in the crowded environment of the nucleolus (Szebeni and pression (Bargou et al., 1996). Furthermore, inability to activate
NF-B in ALCL cell lines results in differences in biological re-Olson, 1999).
ALK is a receptor tyrosine kinase, the expression of which sponses to CD30 activation (Mir et al., 2000). Since aberrant
S I G N I F I C A N C E
The chimeric oncoprotein NPM-ALK has transforming capacity through its tyrosine kinase activity. This study provides evidence for
a novel function of this chimeric tyrosine kinase oncoprotein, presumably based on the chaperone activity of the partner domain,
an insight into the function of chimeric tyrosine kinases in lymphomagenesis. Furthermore, NPM-ALK induction of an ALCL-like
phenotype in H-RS cells of T lymphocyte origin provides insight into the pathology of HL and ALCL, and the foundation for a conceptual
classification of lymphomas with high CD30 expression.
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expression of various cytokines in HL cells is considered to be
dependent mainly on NF-B activation, presence or absence of
NF-B activation in HL and ALCL cells may explain differences in
clinical symptoms and lymph node histology between these
lymphomas (Leoncini et al., 1990).
Tumor necrosis factor receptor (TNFR)-associated factor
(TRAF) proteins are adaptor molecules that associate with the
cytoplasmic region of TNFR superfamily members, and link
these receptors with downstream kinase cascades. Thus far,
six TRAF proteins, TRAF1 to TRAF6, have been identified, of
which TRAF4 is not known to interact with any receptors (Inoue
et al., 2000; Wajant et al., 2001). Ligation of TNF superfamily
members with their cognate receptors leads to recruitment of
a defined set of TRAF proteins to the receptors, which results
in activation of transcription factors, nuclear factor B (NF-B),
and activator protein-1 (AP-1) (Baud et al., 1999; Malinin et
al., 1997; Nishitoh et al., 1998). The cytoplasmic tail of CD30
interacts with TRAF 1, 2, 3, and 5, among which TRAF2 and
TRAF5 can mediate signals that activate NF-B (Horie and Wa-
tanabe, 1998; Schneider and Hubinger, 2002). Transcription
factors activated by TRAF signaling can induce expression of
target genes involved in various aspects of cellular and immune
functions. In addition, activation of NF-B and AP-1 has been
shown to protect cells from apoptosis via transcription of anti-
apoptotic genes (Beg and Baltimore, 1996; Minden and Karin,
1997). Thus, TRAF-mediated signals play important roles in reg-
ulating cell survival, proliferation, and stress responses.
In previous studies, we demonstrated that ligand-indepen-
dent signaling by overexpressed CD30 is abrogated by trans- Figure 1. Absence of NF-B activation and TRAF protein aggregation in ALCL
duction of a decoy CD30 lacking the cytoplasmic region, which cells
causes downregulation of IL-13 and induces apoptosis of H-RS A: NF-B is not activated in ALCL cell lines in the presence of high levels of
cells (Horie et al., 2002b). We further demonstrated that cyto- CD30 expression. a and b: Northern blot analysis of CD30 (a) and GAPDH
transcripts (b). c and d: immunoblot analysis of CD30 protein (c) and NPM-plasmic aggregation of TRAF proteins and colocalization of NIK,
ALK (d). e: EMSA with NF-B probe.IKK, and IB with TRAF aggregates mediates continuous sig-
B: Analysis by confocal microscopy of TRAF proteins in ALCL cells. SR786,naling by the overexpressed CD30 (Horie et al., 2002a).
SUDHL-1 and Karpas 299 are ALCL cell lines, whereas L540 is an H-RS cell
Constitutive activation of NF-B appears to be a basis for line of T cell origin. Right two columns show representative results of biopsied
the characteristic clinical features of HL and proliferation of lymph nodes of ALCL and Hodgkin’s lymphoma (HL).
H-RS cells. Absence of NF-B activation in the presence of
comparable levels of CD30 expression in ALCL cells suggests
that expression of the chimeric oncoprotein NPM-ALK may ex-
plain different consequences of CD30 signaling in HL and ALCL. et al., 2002a, 2002b, 2003). However, in ALCL cells, no NF-B
To study the molecular mechanisms that discriminate between activation is observed in the presence of high levels of CD30
ALCL and H-RS cells, we here characterize the function of NPM- expression (Bargou et al., 1996). These data suggest differences
ALK in terms of the CD30-TRAF-NF-B signaling pathway. The in CD30 signaling between ALCL cells and H-RS cells. To under-
results reveal a blockade of CD30 signaling by NPM-ALK, which stand the mechanisms for these differences, we first confirmed
depends on both ALK kinase activity and presence of the the expression levels of CD30 and the status of NF-B activation
N-terminal NPM domain. It is further shown that wild-type NPM in cell lines derived from ALCL and HL. Northern blot and immu-
can be phosphorylated by NPM-ALK. Association of TRAF2 noblot analyses did not show any appreciable differences in
with CD30 is inhibited by wild-type NPM in the presence of the levels of CD30 expression among cell lines derived from
NPM-ALK in a dose-dependent manner. Moreover, transduc- ALCL and H-RS cells. An HEK293 transformant (293CD30)
tion of NPM-ALK into H-RS cell lines of T lymphocyte origin showed a similar level of CD30 expression compared with H-RS
induces morphological and phenotypic changes characteristic
cell lines (Figures 1Aa–1Ac). NF-B activation in H-RS cell linesof ALCL cells. These results reveal a unique function of the
and 293CD30 cells was clearly demonstrated by electrophoreticchimeric NPM-ALK tyrosine kinase oncoprotein and indicate
mobility shift assay (EMSA), but not in ALCL cell lines that ex-that NPM-ALK modulates the phenotype of CD30-expressing
press NPM-ALK chimeric oncoprotein (Figures 1Ad and 1Ae).tumor cells.
Since we previously demonstrated CD30 signal-dependent
cytoplasmic aggregation of TRAF proteins in H-RS cells (HorieResults
et al., 2002a, 2002b), we next examined aggregation of TRAF
proteins in ALCL cell lines by laser confocal immunofluores-Lack of NF-B activation and TRAF protein
cence microscopy. In all three ALCL cell lines studied, no aggre-aggregation in ALCL cells
gation of TRAF2 and TRAF5 was observed, showing diffuseHigh expression of CD30 triggers ligand-independent signaling
in H-RS cells, resulting in constitutive activation of NF-B (Horie distribution in the cytoplasm, whereas in a H-RS cell line, L540,
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aggregation of TRAF proteins was evident as previously re- To investigate whether the CD30-NF-B signaling pathway
is affected downstream of TRAF proteins in ALCL cells, we nextported (Figure 1B). Immunoblot analysis showed no differences
examined NF-B activation by overexpression of TRAF proteins.in the expression levels of TRAF proteins among cell lines de-
When Karpas 299 and SUDHL-1 ALCL cells were used, overex-rived from ALCL and H-RS cells (data not shown). Then, we
pression of TRAF proteins activated the NF-B-driven promoterstudied distribution of TRAF proteins in biopsied lymph nodes
3- to 5-fold, as was observed in other cell lines (Figure 2D).(LN) of ALCL patients. Five LN samples of ALCL and the same
Furthermore, transduced TRAF2 protein showed cytoplasmicnumber of LN of HL as controls were included. No aggregation
aggregation in these cells (Figure 2E). Thus, overexpression ofof TRAF proteins was observed in ALCL cells, whereas TRAF
TRAF proteins in ALCL cells can activate NF-B by overcomingaggregation was clearly demonstrated in H-RS cells in the LN
the inhibitory activity of NPM-ALK. These results indicate thatof HL. Representative results are shown in Figure 1B. These
the signal transduction pathway downstream of TRAF proteinsin vitro and in vivo observations suggest that CD30-NF-B sig-
is not affected in these ALCL cell lines.naling pathway is interrupted downstream of CD30 and up-
stream of TRAF proteins in ALCL cells. These data also suggest
Interaction of NPM-ALK with TRAF proteinsthat CD30 signaling may be affected by the presence of the
We next tested the possibility that NPM-ALK may inhibit recruit-chimeric oncoprotein NPM-ALK (Figure 1Ae).
ment and aggregation of TRAF proteins by binding to them.
Coimmunoprecipitation studies of ALCL cell lines demonstratedNPM-ALK interrupts association of TRAF2
association of endogenous NPM-ALK with TRAF2 (Figure 3A),with the cytoplasmic tail of CD30
as well as with TRAF5 (data not shown). We next tried to clarifyWe previously showed that in H-RS cells, highly expressed
the domain of NPM-ALK required for this association. UsingCD30 recruits TRAF proteins to the cytoplasmic tail, leading to
expression vectors for NPM-ALK and a series of NPM-ALKligand-independent signaling (Horie et al., 2002b). Since CD30-
mutants, including a kinase-negative mutant of NPM-ALK, asso-overexpressing ALCL cells do not show NF-B activation, we
ciation of these proteins with TRAF2 was examined. Anti-TRAF2next tested the possibility that NPM-ALK may interfere with the
antibody coimmunoprecipitated both the wild-type and kinase-association between TRAF proteins and the cytoplasmic tail of
negative NPM-ALK. The ALK domain alone was also coimmuno-CD30. In transiently transfected HEK293 cells, coimmunopreci-
precipitated with TRAF2, whereas the NPM domain was notpitation of CD30 and TRAF2 was clearly detected as reported
(Figure 3B). Thus, NPM-ALK appears to interact with TRAF2 atpreviously. However, when NPM-ALK was transduced simulta-
the ALK domain, irrespective of its kinase activity.neously with these proteins, the amount of coimmunoprecipi-
Coimmunoprecipitation studies using C-terminally deletedtated TRAF2 was greatly diminished, although not totally abol-
NPM-ALK mutants revealed that the ALK kinase domain is re-ished (Figure 2A, left upper panel). Thus, we next studied
quired for association with TRAF2 (Figure 3C). Thus, we nextassociation of endogenous TRAF proteins with CD30 in ALCL
searched for the consensus TRAF binding motif (Ye et al., 1999)cell lines. No coimmunoprecipitation was observed in these
within the kinase domain of ALK and found a motif of SNQEcells, whereas it was clearly demonstrated in H-RS cell lines
(394–397 aa of NPM-ALK). Coimmunoprecipitation studies us-(Figure 2A, right upper panel). These results, as well as the
ing a mutant of the TRAF binding domain demonstrated lossabsence of cytoplasmic aggregation of TRAF proteins in ALCL
of association between TRAF2 and NPM-ALK (Figure 3D). Takencells as demonstrated above, suggest that NPM-ALK interferes
together, these results revealed that TRAF2 associates withwith the interaction between CD30 and TRAF proteins, and also
NPM-ALK at the consensus binding motif located in the ALKbetween TRAF proteins.
kinase domain.Next we tested NF-B activation by transient reporter gene
As shown above, NF-B activation induced by CD30 overex-assays using a luciferase construct with an NF-B driven pro-
pression was inhibited by coexpression of wild-type NPM-ALK
moter. Transduction of NPM-ALK inhibited NF-B activation
but not by a kinase-negative mutant of NPM-ALK (KN-NPM-
induced by CD30 overexpression. However, this inhibition was ALK) (Figure 2B). We next studied functional effects of the NPM
not observed when a kinase-negative mutant of NPM-ALK was or ALK domains on the NF-B-driven promoter. Expression of
coexpressed (Figure 2B, left panel). Transduction of the wild- the NPM domain alone did not show a significant suppression
type NPM-ALK, but not a kinase-negative mutant, inhibited NF- of NF-B-driven promoter activities, nor did the ALK domain
B activation in L540 and 293CD30 cell lines where NF-B is alone (Figure 3E). Similarly, expression of a TRAF binding-defi-
constitutively activated (Figure 2B, right panel). Thus, NPM-ALK cient mutant of NPM-ALK did not show interference with CD30-
appears to inhibit the CD30-NF-B signaling pathway as a result mediated activation of NF-B (data not shown). These results
of its kinase activity. indicate the interaction of ALK with TRAF proteins is not suffi-
We next examined whether recruitment and aggregation of cient to inhibit CD30 signaling, but suggest that both the kinase
TRAF proteins are inhibited by NPM-ALK. Distribution of TRAF activity and the chimeric structure of NPM-ALK are required for
proteins in L540 and 293CD30 cells was studied by laser confo- the inhibition.
cal immunofluorescence microscopy after transduction of wild-
type NPM-ALK or a kinase-negative mutant. Expression of wild- ALK chimeras other than NPM-ALK cannot
type NPM-ALK resulted in diffuse distribution of TRAF2 in the inhibit NF-B activation
cytoplasm, whereas TRAF2 showed cytoplasmic and juxta- Variants of the ALK chimeric protein, TPM3-ALK and TFG-ALK,
membrane aggregation in the presence of a kinase-negative have been reported in a minority of ALCL (Hernandez et al.,
NPM-ALK (Figure 2C). Taken together, these results support the 1999; Lamant et al., 1999). The ALK of these chimeras is be-
hypothesis that NPM-ALK inhibits the CD30-NF-B signaling lieved to be activated by oligomerization through the partner
pathway by blocking recruitment and aggregation of TRAF pro- domains. To elucidate the functional roles of the NPM domain,
we next studied the activities of these variant ALK chimeras onteins.
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Figure 2. Inhibition of CD30 signaling by NPM-ALK
A: NPM-ALK inhibits interaction between CD30
and TRAF proteins. Upper panels, immunoprecip-
itates with anti-CD30 antibody were blotted by
anti-TRAF2 or anti-CD30 antibodies; lower panels,
whole cell lysates were blotted with antibodies
against proteins indicated on the right. Left
panel, coimmunoprecipitation analysis of tran-
siently overexpressed CD30 and TRAF2 using
HEK293T cells. Right panel, coimmunoprecipita-
tion analysis of endogenous CD30 and TRAF2. IP,
immunoprecipitation; IB, immunoblotting; ly-
sates, whole cell lysates. The asterisk indicates
the position of the Ig heavy chain.
B: Reporter gene analysis with [kB]6-Luc plasmid.
Left panels, transient transfection assays in
HEK293 cells. KN-NPM-ALK, a kinase negative mu-
tant of NPM-ALK. Left upper panel, results of tripli-
cate experiments are shown with the mean and
standard deviation. A representative result of
three independent experiments is presented.
Left lower panels, immunoblot analysis of whole
cell lysates with anti-CD30 or anti-FLAG M2 anti-
body. IB, immunoblotting; lysates, whole cell ly-
sates. Right panels, transient transfection assays
using cell lines with ligand-independent signaling
of CD30. Right upper panel, results of triplicate
experiments are shown with the mean and stan-
dard deviation. A representative result of four
independent experiments is presented. L540, an
H-RS cell line of T cell origin; 293CD30, a stable
transformant of HEK 293 cells highly expressing
CD30. Right lower panels, immunoblot analysis
of whole cell lysates with anti-FLAG M2 antibody.
IB, immunoblotting; lysates, whole cell lysates.
C: Analysis by confocal microscopy of distribu-
tion of endogenous TRAF2. Antibodies used are
indicated on the top. Expression plasmids trans-
fected are shown below the panel. Arrows show
the cells expressing the transduced proteins.
D: Reporter gene assays with [kB]6-Luc plasmid
using ALCL cell lines. Upper panel, results of tripli-
cate dual luciferase assays are shown. A repre-
sentative result of three independent exper-
iments is presented. Transfected expression
plasmids are indicated below the graph. Lower
panel, immunoblot analysis of whole cell lysates
with anti-FLAG M2. IB, immunoblotting; lysates,
whole cell lysates.
E: Analysis by confocal microscopy of TRAF2 dis-
tribution in ALCL cell lines transfected with TRAF2
expression vector.
the CD30 signaling pathway. In transient reporter gene assays 293CD30 cells after transduction of NPM-ALK or TPM3-ALK pro-
tein. Cytoplasmic aggregation of TRAF2 did not show any changesusing an NF-B-driven luciferase construct and HEK293 cells,
these chimeric ALK proteins did not inhibit NF-B activation by in the presence of TPM3-ALK protein, whereas it disappeared
in cells transduced with NPM-ALK (Figure 4C). Thus, NPM-ALKCD30 (Figure 4A). Instead, transduction of TPM3-ALK or TFG-
ALK enhanced NF-B-driven luciferase activities about 2- to appears to inhibit NF-B activation by blocking the aggregation
of TRAF proteins, and other ALK-chimeras cannot inhibit NF-B3-fold compared with that due to CD30 alone. Lack of inhibitory
activities of these chimeric proteins on NF-B activation was because of the lack of inhibition of TRAF aggregation.
also observed when they were transduced into L540 cells (Figure
4B) or 293CD30 cells (data not shown). We next examined Identification of the wild-type NPM as the kinase
substrate of NPM-ALKwhether these chimeric proteins can induce changes in the
intracellular distribution of TRAF proteins. To this end, we stud- To elucidate the mechanism for inhibition of TRAF aggregation
and signaling pathway by NPM-ALK, we next studied the targetied by confocal immunofluorescence microscopy L540 and
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Figure 3. Association of NPM-ALK with TRAF2 and
determination of TRAF2 binding region
A: Coimmunoprecipitation analysis of endoge-
nous TRAF2 and NPM-ALK in ALCL cells. Upper
two panels, immunoprecipitates of anti-TRAF2
antibody were blotted with anti-ALK or anti-
TRAF2 antibody. Lower two panels, whole cell
lysates were blotted by anti-ALK or anti-TRAF2
antibodies. IP, immunoprecipitation; IB, immu-
noblotting.
B and C: Analysis of the TRAF binding region
in NPM-ALK. Results of coimmunoprecipitation
studies of transiently overexpressed proteins in
293T cells are presented. Schematic figures of
expression plasmids of FLAG-tagged proteins
are presented above figures. Numbers indicate
those of NPM-ALK amino acids. Arrowhead,
kinase-negative mutation. B: Upper two panels,
immunoprecipitates of anti-TRAF2 antibody were
blotted with anti-FLAG M2 or anti-TRAF2 anti-
body. Lower two panels, whole cell lysates were
blotted by M2 or anti-TRAF2 antibody. Right sep-
arated panels, NPM domain protein was sepa-
rately analyzed with 10% SDS-PAGE. Arrowheads
indicate positions of FLAG-tagged proteins. As-
terisk shows the position of Ig heavy chain. IP,
immunoprecipitation; IB, immunoblotting; ly-
sates, whole cell lysates. C: Coimmunoprecipita-
tion analysis with C-terminally deleted NPM-ALK
proteins. Left lower panels, immunoprecipitates
of anti-TRAF2 antibody were blotted by anti-
FLAG M2 antibody (upper left panel) or anti-
TRAF2 antibody (lower left panel). Right lower
panels, expression of transduced proteins were
confirmed by blotting of whole cell lysates with
M2 antibody (upper right panel) or anti-TRAF2
antibody (lower right panel). Arrowheads indi-
cate positions of FLAG-tagged proteins. IB, im-
munoblotting; lysates, whole cell lysates.
D: Coimmunoprecipitation analysis of a mutant
NPM-ALK. NPM-mALK has a mutated TRAF bind-
ing consensus sequence in the kinase domain.
Upper two panels, immunoprecipitates of anti-
TRAF2 antibody were blotted by anti-ALK (top
panel) or anti-TRAF2 antibody (second panel).
Lower two panels, expression of transduced con-
structs was confirmed by blotting of whole cell
lysates with anti-ALK (third panel) or anti TRAF2
antibody (bottom panel). IP, immunoprecipita-
tion; IB, immunoblotting; lysates, whole cell lysates.
E: Reporter gene analysis with [kB]6-Luc plasmid using HEK293 Jurkat cells. Top panel, results of dual luciferase assays of triplicate experiments are shown
with the mean and standard deviation. A representative result of three independent experiments is presented. Lower three panels, immunoblot analysis
of whole cell lysates with anti-CD30 (top of lower panels) or anti-FLAG M2 antibody (middle and bottom of lower panels). IB, immunoblotting; lysates, whole
cell lysates.
of the NPM-ALK. Since we demonstrated interaction of TRAF2 negative NPM-ALK. Results clearly showed that wild-type NPM
can be phosphorylated by NPM-ALK (Figure 5A, right upperwith NPM-ALK (Figure 3), we first examined whether TRAF2
can be phosphorylated by NPM-ALK using in vitro kinase assays panel). Treatment of the gel with KOH did not abrogate phos-
phorylation (Figure 5A, right middle panel), excluding the possi-with anti-ALK antibody immunoprecipitates of HEK293T cells
transfected by combinations of expression vectors for NPM- bility that the NPM may be phosphorylated by contaminated
serine/threonine kinases.ALK, TRAF2, and wild-type NPM. Results did not show a band
corresponding to phosphorylated TRAF2. Instead, a clear band Since the above results suggest that inhibition of TRAF2
association with CD30 may be mediated by functional modula-of about 40 kDa was observed in the autoradiogram when wild-
type NPM was cotransfected (Figure 5A, left panel), suggesting tion of the wild-type NPM by NPM-ALK, we next tested whether
association between TRAF2 and CD30 can be inhibited by trans-that wild-type NPM may be the kinase substrate of NPM-ALK.
To test this possibility, we performed a kinase assay using a duced wild-type NPM in the presence of NPM-ALK in a dose-
dependent manner. Results of coimmunoprecipitation assaysbacterially expressed recombinant NPM as substrate and an
anti-ALK antibody immunoprecipitate of HEK293T cells trans- clearly demonstrated dose-dependent inhibition by transduced
NPM, but no inhibition was observed by transduction of afected with an expression vector for NPM-ALK or a kinase-
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marked changes in morphology compared with that of infected
control cells. NPM-ALK transformants appeared larger in size
and showed more abundant basophilic cytoplasm with numer-
ous vacuoles, and prominent nucleoli. These characteristics are
shared with ALCL cell lines, Karpas 299 and SUDHL-1 (Figure
6A). Next, we studied these NPM-ALK transformants for expres-
sion of ALCL marker proteins such as EMA and Clusterin (Jaffe,
2001). Laser confocal immunofluorescence microscopy clearly
demonstrated induction or upregulation of EMA and Clusterin
in these transformants (Figure 6B, upper panels). These marker
proteins were shown to be expressed in a very similar pattern
to that of ALCL cell lines (Figure 6B, lower panel). Immunoblot
analysis of HDML2 transformants confirmed induction of EMA
and Clusterin (Figure 6C). The same results were obtained when
we characterized NPM-ALK transformants of a Mac1 cell line
that is a cutaneous ALCL-derived T cell line with CD30 overex-
pression and without NPM-ALK (data not shown and Willers et
al., 2003). The results suggest that phenotypic changes induced
by NPM-ALK are not limited to HL-derived T cell lines, but are
observed in other CD30 highly expressing T cell lines from ALCL
without NPM-ALK.
Characteristics of signal transduction
in NPM-ALK transformants
We next studied changes in the CD30 signal transduction in
NPM-ALK transformants. As expected, the transformants
showed loss of NF-B binding activity in EMSA, whereas those
infected with a vacant retrovirus vector clearly showed strong
Figure 4. Absence of inhibitory activity of variants of ALK chimeras on CD30 binding activity of NF-B (Figure 7A, top panel). No significant
signaling differences in the levels of CD30 expression were observed
A and B: Upper panels of A and B, reporter gene assays in HEK293 (A) and among these cells (Figure 7A, bottom panel). Disappearance of
L540 (B) cell lines. Results of dual luciferase assays of triplicate experiments
TRAF protein aggregation in the cytoplasm was found in theare shown with the mean and standard deviation. A representative result
NPM-ALK transformants, but not in control cells infected withof three independent experiments is presented. Lower panels of A and B,
immunoblot analysis of whole cell lysates. IB, immunoblotting; lysates, whole a vacant retrovirus vector. Diffuse distribution of TRAF proteins
cell lysates. in the cytoplasm of H-RS cell transformants was similar to that
C: Analysis by confocal microscopy of endogenous TRAF2 distribution. Anti- in ALCL cell lines (Figure 7B). NPM-ALK was expressed in the
bodies used are indicated on the top. Expression plasmids transfected are
cytoplasm and nucleus in the transformants, as is observed inshown below the panel. Arrows show the cells expressing the transduced
ALCL cell lines (Figure 7C). The results provide further supportproteins.
for the hypothesis that TRAF protein aggregation results from
signaling of overexpressed CD30 as previously reported (Horie
et al., 2002a). Next, we examined responses of the NPM-ALK
kinase-negative NPM-ALK (Figure 5B). Next, we examined transformants to CD30 stimulation by CD30 ligand (CD30L).
whether the wild-type NPM is associated with NPM-ALK. Coim- They showed suppression of cell growth after CD30 ligand stim-
munoprecipitation assays demonstrated strong association of ulation as is observed in Karpas 299 (Figure 7D). The results
NPM with NPM-ALK, whereas the kinase-negative NPM-ALK demonstrated that NPM-ALK inhibition of CD30-TRAF-NF-B
showed a decreased level of association (Figure 5C). Associa- signaling pathway results in clear differences in biological ef-
tion between the endogenous wild-type NPM and NPM-ALK fects of CD30 stimulation, and provide an explanation for the
was also demonstrated in ALCL cell lines (Figure 5D), which molecular basis of the previously described differences in re-
excluded the possibility that the association was an artifact sponses to CD30L stimulation between HL and ALCL cell lines
caused by overexpression of transduced proteins. (Mir et al., 2000).
Phenotypic characteristics of stable transformants Discussion
of H-RS cell lines expressing NPM-ALK
Since the above results suggested that expression of NPM-ALK In the present study, we demonstrate a unique function of the
chimeric tyrosine kinase, NPM-ALK, that is expressed in mostmay be critical to determine the phenotype of CD30-overex-
pressing cells, we next examined whether stable transduction ALCL cases. NPM-ALK interferes with CD30 signaling through
blocking recruitment and aggregation of TRAF proteins. NPMof NPM-ALK in H-RS cell lines can induce phenotypic character-
istics similar to ALCL cells in the transformants. Two H-RS cell protein is shown to be phosphorylated by and form complexes
with NPM-ALK. We further found that transduction of NPM-lines of T lymphocyte origin, L540 and HDLM2, were stably
transduced with NPM-ALK using a retrovirus vector. May- ALK into H-RS cell lines of T cell origin can bestow upon them
ALCL-like morphology and induce expression of ALCL markerGruenwald Giemsa staining of the transformants revealed
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Figure 5. Phosphorylation of NPM by NPM-ALK
and association of NPM with NPM-ALK
A: In vitro kinase assays. Left upper two panels,
autoradiogram of kinase assays. Anti-ALK anti-
body immunoprecipitates of HEK293T cells trans-
fected by expression plasmids indicated above
the figure were used for a kinase reaction. Aster-
isk indicates the position of the wild-type NPM
protein. Left lower three panels, immunoblot
analysis of anti-ALK antibody immunoprecipi-
tates (top panel) and whole cell lysates (middle
and bottom panels) with antibodies indicated
on the right. KN, a kinase negative NPM-ALK.
Right panels, results of an in vitro kinase assay
using a bacterially expressed His-tagged wild-
type NPM as a substrate. The wild-type or kinase
negative mutant NPM-ALK was expressed in
HEK293T cells. Top and middle of right panels,
autoradiograms of the kinase reaction mixture
before (top panel) and after (middle panel) KOH
treatment of the gel, respectively. Bottom of right
panels, immunoblot analysis of the kinase reac-
tion mixture. KN, a kinase negative NPM-ALK; IP/
IB, immunoprecipitation and immunoblotting.
B: Wild-type NPM potentiates inhibitory activity
of NPM-ALK against interaction between CD30
and TRAF2. Upper two panels, coimmunopreci-
pitation analysis. Anti-CD30 antibody immuno-
precipitates of HEK293T cells transfected with
plasmids indicated above were blotted with
anti-TRAF2 (top panel) or anti-CD30 antibody
(second panel). Lower three panels, immu-
noblots of whole cell lysates with antibodies indi-
cated on the left. KN, expression plasmid for a
kinase negative NPM-ALK. Closed triangle, 5 and
10 g of FLAG-NPM. IP, immunoprecipitation; IB,
immunoblotting.
C: Association of the wild-type NPM protein with
NPM-ALK. HEK293T cells were transfected by
plasmids indicated above the figure. Upper pan-
els, immunoblot analysis anti-ALK antibody im-
munoprecipitates. Lower panels, immunoblot
analysis of whole cell lysates with anti-FLAG anti-
body. IP, immunoprecipitation; IB, immunoblot-
ting; lysates, whole cell lysates.
D: Coimmunoprecipitation of endogenous wild-
type NPM protein with NPM-ALK. Upper panels,
immunoblot analysis of anti-ALK antibody immu-
noprecipitates. Bottom panel, immunoblot anal-
ysis of whole cell lysates. IP, immunoprecipitation;
IB, immunoblotting; lysates, whole cell lysates.
proteins. Thus, our results suggest that expression of NPM- ALK-mediated inhibition of the CD30-TRAF signaling pathway
that is dependent on ALK kinase activity. The results also revealALK in neoplastic T cells expressing high levels of CD30 may
be a determinant of their phenotype as ALCL, whereas, in the a possible mechanism of inhibition. Recruitment and aggrega-
tion of TRAF proteins appear to be inhibited by chaperone activ-absence of NPM-ALK, they may exhibit a phenotype of H-RS
cells of Hodgkin’s lymphoma. ity of NPM that is incorporated in the macromolecular complex
formed by oligomerization of NPM-ALK and wild-type NPM
(Hingorani et al., 2000); NPM is a chaperone protein that canInterference of NF-B signaling
High levels of CD30 expression on tumor cells characterize both dissociate aggregated proteins. Association of NPM with NPM-
ALK is significantly facilitated by tyrosine phosphorylation ofHodgkin’s lymphoma and ALCL. We previously showed that
this overexpression of CD30 is the basis for constitutive NF-B NPM by NPM-ALK, which may explain the kinase activity-
dependent inhibition of TRAF signaling. In this context, lack ofactivation in H-RS cells through ligand-independent signaling
(Horie et al., 2002b). Thus, absence of NF-B activation in NPM- inhibition by TPM3-ALK and TFG-ALK can be explained by their
inability to block aggregation of TRAF proteins, since partnersALK-positive ALCL cells prompted us to analyze the function
of NPM-ALK in the signal transduction of CD30. of these ALK chimeras do not have chaperone activity. Regula-
tion of NPM chaperone activity through tyrosine phosphoryla-The results of the present study clearly demonstrate NPM-
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Figure 7. Alteration of CD30-TRAF signaling pathway in NPM-ALK trans-
Figure 6. Phenotypic characteristics of stable transformants of H-RS cell lines formants of H-RS cell lines
expressing NPM-ALK
A: Absence of NF-B activation in NPM-ALK expressing transformants. Top
A: Photographs of cells stained with May-Gruenwald Giemsa. Magnifica- panel, EMSA analysis with NF-B probe. Middle and bottom panels, detec-
tion  400. tion of transduced NPM-ALK and CD30 proteins, respectively, by immu-
B and C: Induction of ALCL marker proteins in NPM-ALK-transduced trans- noblot analysis. IB, immunoblotting.
formants of H-RS cell lines. B: Upper panels, confocal immunofluorescence B: Confocal immunofluorescence analysis of TRAF protein distribution in
analysis of transformants. Parental cell lines are indicated on the left. Anti- transformants. SUDHL1 and Karpas 299 ALCL cell lines analyzed with anti-
bodies used are indicated above the photographs. Bottom panel, ALCL TRAF2 antibody; retrovirus vectors used are indicated above photographs;
cell lines stained with antibodies indicated above. pRx-Puro, transformants NPM-ALK, transformants infected with the retrovirus vector having NPM-ALK.
infected with a vacant retrovirus vector; pRx-NPM-ALK-Puro, transformants C: Confocal immunofluorescence analysis of NPM-ALK in transformants.
infected with the retrovirus vector having NPM-ALK. C: Immunoblot analysis SUDHL and Karpas 299 ALCL cell lines analyzed with anti-ALK antibody.
of marker proteins. HDLM2 cells infected with a vacant or NPM-ALK con- D: Cell kinetic analysis after CD30L stimulation. Relative levels of viable cell
taining vector were studied for expression of marker proteins. Whole cell number examined by trypan blue dye exclusion test are presented. Bars
lysates were blotted with anti-clusterin (top panel), EMA (middle panel), indicate standard deviation (SD) of triplicate experiments.
and tubulin (bottom panel) antibodies.
through a consensus binding motif in the kinase domain of ALK
tion by NPM-ALK is a novel finding, although it has previously (amino acids 394 to 397 of NPM-ALK). However, its functional
been reported that functions of NPM can be modulated by significance is not entirely clear at present, since binding is not
various kinases such as CDK2/cyclin-E (Okuda et al., 2000) and dependent on the kinase activity of ALK. Furthermore, TRAF2
CK2 (Szebeni et al., 2003). does not appear to be the primary target of NPM-ALK, since
we could not demonstrate increased levels of tyrosine phos-We further demonstrated binding of TRAF2 with NPM-ALK
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phorylation of TRAF proteins by immunoblotting with an anti-
phosphotyrosine antibody (data not shown) or an in vitro kinase
assay using [-32P] ATP (Figure 5A).
Hubinger et al. reported that NPM-ALK interacts with the
cytoplasmic tail of CD30 through the ALK domain (Hubinger et
al., 2001), suggesting a regulatory function of NPM-ALK on
CD30 signaling. However, the association between NPM-ALK
and CD30 does not appear to be involved in the inhibition of
NF-B, since it was dependent on the NPM domain (Figures
3E, 4A, and 4B).
Our study can help to explain the divergent effects of CD30
crosslinking previously reported in Hodgkin’s lymphoma and
ALCL (Hubinger et al., 2001; Levi et al., 2001; Schneider and
Hubinger, 2002; Willers et al., 2003). In general, CD30 crosslink-
ing caused increased proliferation of T cell type Hodgkin lym-
phoma cell lines but caused apoptosis or cell cycle arrest of
NPM-ALK-positive ALCL cells. In contrast, CD30 crosslinking
Figure 8. Schematic view of NPM-ALK function in ALCL cellsresulted in NF-B activation and stimulation of NPM-ALK nega-
Presence of p80 NPM-ALK in CD30 overexpressing neoplastic T cells cantive cutaneous ALCL.
determine their phenotype through interference with the CD30-TRAF-NF-BCollectively, our results reveal a novel and unique function signaling pathway.
of the chimeric tyrosine kinase oncoprotein, NPM-ALK, although
further studies are required for detailed characterization of the
molecular mechanisms for regulation of the NPM chaperone
activity and the functional significance of TRAF2 association does not appear to be sufficient, since TRAF2 overexpression in
with NPM-ALK. the NPM-ALK transformants did not show phenotypic reversion
(data not shown). Since no detailed characterization of promoter
Induction of phenotypic changes similar to ALCL cells activities of these genes is available at present, precise mecha-
Our results show that transduction of NPM-ALK into H-RS cells
nisms of induction remain to be fully elucidated.
of T-cell origin provides them with an ALCL-like morphology
Our results indicate that the presence or absence of NPM-associated with induction of expression of ALCL marker proteins
ALK chimeric protein in CD30-overexpressing neoplastic T cellsEMA/MUC1 and Clusterin/ApoJ. It has been established that
has a determining effect on their phenotype. These results pro-expression of EMA/MUC1 and Clusterin/ApoJ characterizes
vide a novel insight into understanding the molecular basis ofALK-positive ALCL (Jaffe, 2001). Detection of these two mole-
pathophysiology of these lymphomas and may have an impactcules on tumor cells is important for the pathologic diagnosis
on the classification of CD30-positive lymphomas (Figure 8).and classification of lymphomas. However, regulatory mecha-
There are three categories of lymphoma with closely relatednisms for their gene expression in ALCL cells are largely un-
phenotype: Hodgkin’s lymphoma, ALK-positive and ALK-nega-known.
tive systemic (or nodal) ALCL, and ALK-negative cutaneousEMA/MUC1 is a highly glycosylated type I membrane glyco-
T cell lymphoma. Tumor cells of the latter two categories areprotein that is abundantly expressed on the cell surface of many
human adenocarcinomas like breast and ovarian cancers, and of T cell origin (Stein et al., 2000). All these lymphomas are
in B cell neoplasms such as multiple myeloma and B cell non- characterized by high levels of CD30 expression. A great major-
Hodgkin’s lymphoma (Dyomin et al., 2000; Treon et al., 1999). ity of H-RS cells originate from germinal center B cells, with a
Regulatory mechanisms of EMA/MUC1 expression have not minority of T cell origin H-RS cells (Kadin et al., 2001; Muschen
been characterized, although involvement of tyrosine kinases et al., 2000; Seitz et al., 2000). Thus, our results suggest the
such as c-src and ErbB2 has been suggested (Gonzalez- possibility that NPM-ALK-positive ALCL represents a unique
Guerrico et al., 2002; Scibetta et al., 2001). Clusterin/ApoJ was entity, whereas there might be no clear distinction between HL
recently identified as a marker protein specifically expressed of T cell origin, ALK-negative systemic ALCL, and ALK-negative
in systemic ALCL cells (Wellmann et al., 2000), although the cutaneous T cell ALCL.
specificity of its expression has been questioned by recent re-
ports (Lae et al., 2002; Saffer et al., 2002). Again, there has Experimental procedures
been no clue to understand the mechanisms of Clusterin/ApoJ
Cell culturesexpression.
Jurkat, HEK293, and HEK293T cell lines were obtained from the JapaneseIn the present study, we demonstrate that stable transduc-
Cancer Research Resources Bank (Tokyo, Japan) and Fujisaki Cell Biologytion of NPM-ALK into T cell-derived H-RS cell lines that were
Center (Okayama, Japan). H-RS cell lines, HDLM-2 and L-540, and ALCLnegative for these proteins induces expression of both genes,
cell lines, SUDHL-1, Karpas 299, and SR786 were purchased from thewhereas induction was not observed in NPM-ALK transformants
German Collection of Microorganisms and Cell Cultures (Braunschweig,
of L428, an H-RS cell line of B cell origin in which NF-B activity
Germany). Cutaneous ALCL cell line Mac1 was described previously (Willers
was significantly suppressed (data not shown). The data sug- et al., 2003). Nonadherent cell lines were cultured in RPMI 1640 and adherent
gest that the induction of EMA and Clusterin/ApoJ results from cells in DMEM with supplementation of recommended concentrations of
inhibition of TRAF signaling and introduction of the constitutively fetal calf serum (FCS) and antibiotics. An HEK293 transformant (293CD30)
was described previously (Horie et al., 2002a, 2002b).active tyrosine kinase, ALK. Abrogation of TRAF signaling alone
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Plasmids and cDNA per lane. Probes used were as follows: a 980 bp of CD30 and 838 bp of
GAPDH cDNA fragments amplified by RT-PCR and cloned in pGEM-T vectorExpression vectors for human CD30 and FLAG-tagged TRAF2 and TRAF5
were described elsewhere (Aizawa et al., 1997; Horie et al., 1996, 1998). A (Promega).
cDNA clone for NPM-ALK was obtained by screening of a cDNA library
prepared from Karpas 299 using a probe of ALK cDNA fragment amplified Retrovirus-mediated transduction of NPM-ALK to H-RS cell lines
by reverse transcription PCR (RT-PCR). Expression vectors for the wild-type The NPM-ALK cDNA containing the entire coding region was cloned into
and N-terminally FLAG-tagged NPM-ALK were prepared using pME18S (a retrovirus vector pRx-puro (Wakimoto et al., 1997) and the resultant plasmid
gift from Dr. Maruyama at Tokyo Medical and Dental University) and FLAG- was named pRx-NPM-ALK-puro. Virus-containing supernatants were pre-
tagged expression vector (pME-FLAG), respectively. Those for the NPM or pared using the Phenix-Ampho packaging cell line. Control experiments
ALK domains of NPM-ALK, C-terminally deleted NPM-ALK mutants, and the using pRx-GFP-Puro vector showed transduction efficiency of more than
FLAG-tagged wild-type NPM were prepared using PCR-amplified fragments. 20% for both cell types (data not shown). Transfectants were selected using
Expression vectors for the TPM3-ALK or TFG-ALK fusion proteins were 2 g/ml puromycin (SIGMA). In most transduction experiments, about one-
prepared by introducing PCR-amplified TPM3 or TFG fragments just up- third of cells appeared to survive puromycin selection. NPM-ALK expression
stream of ALK domain of pFLAG-ALK. The resultant plasmids were named was examined by immunoblotting out as described previously.
pFLAG-TPM3-ALK and pFLAG-TFG-ALK. An expression vector for a kinase
negative mutant of NPM-ALK (Y156/567F), pME-FLAG-KN-NPM-ALK, was Cell kinetic analysis
described previously (Fujimoto et al., 1996) and is a gift from Dr. Yamamoto, Two 96-well flat-bottomed microtiter plates (Coaster 3361 high binding) were
The Institute of Medical Science, The University of Tokyo. A FLAG-tagged coated with 50 ng of a human recombinant CD30L (ALEXIS Biochemicals
expression vector for a mutant NPM-ALK having point mutations in the San Diego, CA). After overnight incubation of the plates at 4C, the coating
putative TRAF binding motif, S394A/Q396A/E397A, was prepared by the solution was removed, and 100 l culture medium containing 20,000 cells
method of Kunkel (1985). Primer information is shown in the Supplemental in logarithmic growth conditions was added to each well. To prevent further
Data at http://www.cancercell.org/cgi/content/full/5/4/353/DC1. binding between soluble CD30 and CD30L, the cells were washed and fresh
culture medium added at the time of transfer. The plates were incubated at
Immunohistochemistry 37C in a 5% CO2 atmosphere. After 48 hr, cells were stained by trypan
Immunohistochemical and immunofluorescence analyses of cultured cells blue solution (Biochrom KG, Berlin, Germany) and viable cells were counted.
and biopsied lymph nodes were done as described (Horie et al., 2002b), and
visualized with a confocal microscope (Radiance 2000, BioRad). Antibodies Acknowledgments
used are listed in Table S2 of the Supplemental Data. To detect TRAF and
CD30 proteins in lymph node samples, a modification of the tyramide signal We thank Dr. T. Yamamoto for providing the expression plasmids of the
amplification (TSA) system (NEN Life Science) was used in order to facilitate mutant NPM-ALK and for critical assessment of the manuscript, and M.
use of streptavidine-FITC or streptavidine-Texas Red instead of peroxidase- Maruyama-Nagai and Miyako Taira for excellent technical help. This work
conjugated streptavidine. Antibody information is shown in the Supplemental was supported in part by The Mochida Memorial Foundation for Medical
Data. and Pharmaceutical Research to R.H. and by Grants-in-Aid for Scientific
Research from Japanese Society for Promotion of Science to R.H. and T.W.
Immunoblotting Dr. Kadin is supported by NIH grant P50-CA-93683-02.
Immunoblotting experiments and coimmunoprecipitation were done as de-
scribed (Horie et al., 1996). Transfection was done by Lipofectin reagent
(Invitrogen) using 2  106 HEK293T cells, and total of 2 g of expression
vectors. A vacant expression vector pME18S was used in control transfec- Received: May 27, 2003
tions or to make the total amount of transfected plasmid 2 g. Antibody Revised: December 30, 2003
binding was detected using ECL chemiluminescence kits (Amersham) or Accepted: February 13, 2004
Western blue stabilized substrate for alkaline phosphatase (Promega). Anti- Published: April 19, 2004
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